Sedana Medical AB (OSTO:SEDANA, Financial) is set to release its Q3 2024 earnings on Oct 24, 2024. The consensus estimate for Q3 2024 revenue is $41 million, and the earnings are expected to come in at -$0.18 per share. The full year 2024's revenue is expected to be $181.5 million and the earnings are expected to be -$0.6 per share. More detailed estimate data can be found on the Forecast page.
Sedana Medical AB (OSTO:SEDANA, Financial) Estimates Trends
Over the past 90 days, revenue estimates for Sedana Medical AB (OSTO:SEDANA) for the full year 2024 have been revised downward from $186.5 million to $181.5 million. For 2025, the revenue estimates have also been adjusted from $239.5 million to $238 million. Earnings estimates have been reduced from -$0.59 per share to -$0.6 per share for the full year 2024, and from -$0.43 per share to -$0.44 per share for 2025.
Sedana Medical AB (OSTO:SEDANA, Financial) Reported History
In the previous quarter of 2024-06-30, Sedana Medical AB's (OSTO:SEDANA) actual revenue was $41.06 million, which missed analysts' revenue expectations of $45 million by -8.76%. Sedana Medical AB's (OSTO:SEDANA) actual earnings were -$0.18 per share, which missed analysts' earnings expectations of -$0.13 per share by -38.46%. After releasing the results, Sedana Medical AB (OSTO:SEDANA) was down by -11.53% in one day.
Sedana Medical AB (OSTO:SEDANA, Financial) 12 Month Price Targets
Based on the one-year price targets offered by 1 analyst, the average target price for Sedana Medical AB (OSTO:SEDANA) is $43 with a high estimate of $43 and a low estimate of $43. The average target implies an upside of 90.27% from the current price of $22.60.
Based on GuruFocus estimates, the estimated GF Value for Sedana Medical AB (OSTO:SEDANA, Financial) in one year is $39.85, suggesting an upside of 76.33% from the current price of $22.60.
Based on the consensus recommendation from 1 brokerage firm, Sedana Medical AB's (OSTO:SEDANA, Financial) average brokerage recommendation is currently 2.0, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
